Tuftsin-bearing liposomes in treatment of macrophage-based infections
Identifieur interne : 002435 ( Main/Exploration ); précédent : 002434; suivant : 002436Tuftsin-bearing liposomes in treatment of macrophage-based infections
Auteurs : Ajay K. Agrawal [Royaume-Uni] ; C. M Gupta [Inde]Source :
- Advanced Drug Delivery Reviews [ 0169-409X ] ; 2000.
English descriptors
- Teeft :
- Academic press, Agents chemother, Agrawal, Amphotericin, Antifungal agents, Antifungal drugs, Antileishmanial, Antileishmanial activity, Antimicrob, Antitubercular activity, Antitubercular drugs, Biological activity, Bone marrow, Cellular membranes, Chemother, Chemotherapy, Chloroquine, Chloroquine encapsulated, Chloroquine resistance, Cholesterol content, Cholesterol tuftsin liposomes, Defence, Donovani, Donovani infections, Dos, Drug carrier syst, Drug carriers, Drug concentration, Drug delivery, Drug delivery reviews, Drug delivery system, Drug delivery systems, Drug dose, Drug doses, Drug encapsulated, Drug resistance, Drug target, Drug tolerance, Drug toxicity, Drug vehicles, Elsevier science, Encapsulated, Erythrocyte, Febs lett, Free drug, Fungal, Fungal chemotherapy, Fungal disease, Fungal infections, Further increase, Gene delivery, Gupta, Heavy chain, Host defence, Infection, Intracellular infections, Kupffer cells, Leishmania donovani, Leishmania donovani infections, Leishmaniasis, Liposomal, Liposomal amphotericin, Liposomal tuftsin, Liposomal vaccines, Liposome, Liposome surface, Liposomes bilayer, Liposomised, Liposomised drug, Macrophage, Macrophages monocytes, Major front line drugs, Malaria, Malarial infection, Marcel dekker, Mononuclear phagocyte system, Mononuclear phagocytes, Multiple treatment regimens, Murine malaria, Mycobacterial infections, Mycobacterium, Mycobacterium tuberculosis, Parasite, Peptide, Phagocytic cells, Plasmodium, Plasmodium falciparum, Pulmonary tuberculosis, Rifampin, Serum proteins, Side effects, Single dose, Single treatment, Survival times, Toxicity, Tuberculous mice, Tuftsin, Tuftsin analogs, Tuftsinbearing liposomes, Undesirable effects, Unpublished observations, Vaccine, Visceral leishmaniasis.
Abstract
Abstract: The use of liposomes as drug carriers in treatment of various diseases has been explored extensively for more than 20 years. ‘Conventional’ liposomes, when administered in vivo by a variety of routes, rapidly accumulate in the mononuclear phagocyte system (MPS). The inherent tendency of the liposomes to concentrate in MPS can be exploited in enhancing the non-specific host defence against infections by entrapping in them the macrophage modulators, and as carriers of antibiotics in treatment of intracellular infections that reside in MPS. This must further be enhanced by grafting on the liposome surface the ligands, e.g. tuftsin, that not only binds specifically to the MPS cells but also enhances their natural killer activity. Keeping this in view, we designed and developed tuftsin-bearing liposomes as drug carriers for the treatment of macrophage-based infections and outline these studies in this overview.
Url:
DOI: 10.1016/S0169-409X(99)00061-7
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F66
- to stream Istex, to step Curation: 000F66
- to stream Istex, to step Checkpoint: 001250
- to stream Main, to step Merge: 002462
- to stream Main, to step Curation: 002435
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Tuftsin-bearing liposomes in treatment of macrophage-based infections</title><author><name sortKey="Agrawal, Ajay K" sort="Agrawal, Ajay K" uniqKey="Agrawal A" first="Ajay K" last="Agrawal">Ajay K. Agrawal</name></author><author><name sortKey="Gupta, C M" sort="Gupta, C M" uniqKey="Gupta C" first="C. M" last="Gupta">C. M Gupta</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9443EAD07862D6D7512D9A308B4DA4566D9D84D3</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0169-409X(99)00061-7</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-N3T7PW27-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000F66</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F66</idno><idno type="wicri:Area/Istex/Curation">000F66</idno><idno type="wicri:Area/Istex/Checkpoint">001250</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001250</idno><idno type="wicri:doubleKey">0169-409X:2000:Agrawal A:tuftsin:bearing:liposomes</idno><idno type="wicri:Area/Main/Merge">002462</idno><idno type="wicri:Area/Main/Curation">002435</idno><idno type="wicri:Area/Main/Exploration">002435</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Tuftsin-bearing liposomes in treatment of macrophage-based infections</title><author><name sortKey="Agrawal, Ajay K" sort="Agrawal, Ajay K" uniqKey="Agrawal A" first="Ajay K" last="Agrawal">Ajay K. Agrawal</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>PolyMASC Pharmaceuticals Plc, Fleet Road, London NW3 2EZ</wicri:regionArea><wicri:noRegion>London NW3 2EZ</wicri:noRegion></affiliation></author><author><name sortKey="Gupta, C M" sort="Gupta, C M" uniqKey="Gupta C" first="C. M" last="Gupta">C. M Gupta</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Central Drug Research Institute, Lucknow 226001</wicri:regionArea><wicri:noRegion>Lucknow 226001</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Advanced Drug Delivery Reviews</title><title level="j" type="abbrev">ADR</title><idno type="ISSN">0169-409X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">41</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="135">135</biblScope><biblScope unit="page" to="146">146</biblScope></imprint><idno type="ISSN">0169-409X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0169-409X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Academic press</term><term>Agents chemother</term><term>Agrawal</term><term>Amphotericin</term><term>Antifungal agents</term><term>Antifungal drugs</term><term>Antileishmanial</term><term>Antileishmanial activity</term><term>Antimicrob</term><term>Antitubercular activity</term><term>Antitubercular drugs</term><term>Biological activity</term><term>Bone marrow</term><term>Cellular membranes</term><term>Chemother</term><term>Chemotherapy</term><term>Chloroquine</term><term>Chloroquine encapsulated</term><term>Chloroquine resistance</term><term>Cholesterol content</term><term>Cholesterol tuftsin liposomes</term><term>Defence</term><term>Donovani</term><term>Donovani infections</term><term>Dos</term><term>Drug carrier syst</term><term>Drug carriers</term><term>Drug concentration</term><term>Drug delivery</term><term>Drug delivery reviews</term><term>Drug delivery system</term><term>Drug delivery systems</term><term>Drug dose</term><term>Drug doses</term><term>Drug encapsulated</term><term>Drug resistance</term><term>Drug target</term><term>Drug tolerance</term><term>Drug toxicity</term><term>Drug vehicles</term><term>Elsevier science</term><term>Encapsulated</term><term>Erythrocyte</term><term>Febs lett</term><term>Free drug</term><term>Fungal</term><term>Fungal chemotherapy</term><term>Fungal disease</term><term>Fungal infections</term><term>Further increase</term><term>Gene delivery</term><term>Gupta</term><term>Heavy chain</term><term>Host defence</term><term>Infection</term><term>Intracellular infections</term><term>Kupffer cells</term><term>Leishmania donovani</term><term>Leishmania donovani infections</term><term>Leishmaniasis</term><term>Liposomal</term><term>Liposomal amphotericin</term><term>Liposomal tuftsin</term><term>Liposomal vaccines</term><term>Liposome</term><term>Liposome surface</term><term>Liposomes bilayer</term><term>Liposomised</term><term>Liposomised drug</term><term>Macrophage</term><term>Macrophages monocytes</term><term>Major front line drugs</term><term>Malaria</term><term>Malarial infection</term><term>Marcel dekker</term><term>Mononuclear phagocyte system</term><term>Mononuclear phagocytes</term><term>Multiple treatment regimens</term><term>Murine malaria</term><term>Mycobacterial infections</term><term>Mycobacterium</term><term>Mycobacterium tuberculosis</term><term>Parasite</term><term>Peptide</term><term>Phagocytic cells</term><term>Plasmodium</term><term>Plasmodium falciparum</term><term>Pulmonary tuberculosis</term><term>Rifampin</term><term>Serum proteins</term><term>Side effects</term><term>Single dose</term><term>Single treatment</term><term>Survival times</term><term>Toxicity</term><term>Tuberculous mice</term><term>Tuftsin</term><term>Tuftsin analogs</term><term>Tuftsinbearing liposomes</term><term>Undesirable effects</term><term>Unpublished observations</term><term>Vaccine</term><term>Visceral leishmaniasis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The use of liposomes as drug carriers in treatment of various diseases has been explored extensively for more than 20 years. ‘Conventional’ liposomes, when administered in vivo by a variety of routes, rapidly accumulate in the mononuclear phagocyte system (MPS). The inherent tendency of the liposomes to concentrate in MPS can be exploited in enhancing the non-specific host defence against infections by entrapping in them the macrophage modulators, and as carriers of antibiotics in treatment of intracellular infections that reside in MPS. This must further be enhanced by grafting on the liposome surface the ligands, e.g. tuftsin, that not only binds specifically to the MPS cells but also enhances their natural killer activity. Keeping this in view, we designed and developed tuftsin-bearing liposomes as drug carriers for the treatment of macrophage-based infections and outline these studies in this overview.</div></front></TEI><affiliations><list><country><li>Inde</li><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Agrawal, Ajay K" sort="Agrawal, Ajay K" uniqKey="Agrawal A" first="Ajay K" last="Agrawal">Ajay K. Agrawal</name></noRegion></country><country name="Inde"><noRegion><name sortKey="Gupta, C M" sort="Gupta, C M" uniqKey="Gupta C" first="C. M" last="Gupta">C. M Gupta</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9443EAD07862D6D7512D9A308B4DA4566D9D84D3
|texte= Tuftsin-bearing liposomes in treatment of macrophage-based infections
}}
| This area was generated with Dilib version V0.6.33. |  |